UVM Reference Number: C852
Summary:
A method of preserving cardiovascular integrity to limit long-term damage after myocardial infarction and other ischemic events
Background:
Compromised distal myocardial perfusion is commonly observed in 25-30% of patients with acute myocardial infarction (MI) despite action to restore blood flow in local lay vessels via thrombolytics and PCI/stenting. No treatments are currently available that preserve this vascular integrity after MI.
Technology Overview:
University of Vermont researchers have shown that treatment with a defined HGF/IgG complex, “VasoPlex” reduces infarct size and adverse ventricular remodeling and dysfunction after reperfusion, improving cardiac perfusion and outcomes in both rat and pig models of MI. VasoPlex provides a novel approach to preserving vascular integrity that may substantially limit long-term damage in a wide spectrum of patients, both after MI and in other ischemic events, such as stroke and organ transplant.
Further Details:
Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury. Rao KS et al PMC4565990
Benefits:
- Defined, peptide-based vaso-protectant.
- Promotes vascular integrity and protection post-MI.
- Reduces infarct expansion and tissue damage.
- Limits long-term damage of reperfusion.
Applications:
- Reduction of reperfusion injury in MI.
- May also be useful in peripheral artery disease, stroke and organ transplants.
Patents:
- US Patent Nos. 10,239,926 and 11,111,282B2
- EP Patent Application EP3261659A4
Seeking:
- Licensing
- Development partner
- University spinout
